Phase II Study of Irinotecan Plus Panitumumab as Second‐Line Therapy for Patients with Advanced Esophageal Adenocarcinoma

LESSON LEARNED. Panitumumab plus irinotecan is not active for the treatment of esophageal adenocarcinoma. BACKGROUND. Esophageal adenocarcinoma (EAC) is a lethal cancer with increasing incidence. Panitumumab (Pa) is a fully humanized IgG2 monoclonal antibody against human EGFR. Cetuximab (Cx) combin...

Descripción completa

Detalles Bibliográficos
Autores principales: Yoon, Harry, Karapetyan, Lilit, Choudhary, Anita, Kosozi, Ramla, Bali, Gurvinder Singh, Zaidi, Ali H., Atasoy, Ajlan, Forastiere, Arlene A., Gibson, Michael K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AlphaMed Press 2018
Materias:
Clinical Trial Results
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6192615/
https://www.ncbi.nlm.nih.gov/pubmed/29769385
http://dx.doi.org/10.1634/theoncologist.2017-0657

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6192615/
https://www.ncbi.nlm.nih.gov/pubmed/29769385
http://dx.doi.org/10.1634/theoncologist.2017-0657

Ejemplares similares